CDA | Evidence Driven
CDA | Evidence Driven

Venclexta for Chronic Lymphocytic Leukemia – Details

Details

Files
Generic Name:
Venetoclax
Project Status:
Complete
Therapeutic Area:
Chronic Lymphocytic Leukemia
Manufacturer:
AbbVie Corporation
Brand Name:
Venclexta
Project Line:
Reimbursement Review
Project Number:
PC0105-000
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Strength:
10mg, 50 mg & 100mg tablet
Tumour Type:
Leukemia
Indications:
Chronic Lymphocytic Leukemia
Funding Request:
As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and who have failed a B-Cell Receptor Inhibitor (BCRi)
Sponsor:
AbbVie Corporation
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Venetoclax (Venclexta) CLL – pERC Final Recommendation Final Recommendation March 2, 2018 View PDF
Venetoclax (Venclexta) CLL – Final Clinical Guidance Report Guidance Reports March 2, 2018 View PDF
Venetoclax (Venclexta) CLL – Final Economic Guidance Report Guidance Reports March 2, 2018 View PDF
Venetoclax (Venclexta) CLL – pERC Initial Recommendation Initial Recommendation November 30, 2017 View PDF
Venetoclax (Venclexta) CLL – PAG Feedback on Initial Recommendation Feedback March 2, 2018 View PDF
Venetoclax (Venclexta) CLL – Manufacturer Feedback on Initial Recommendation Feedback March 2, 2018 View PDF
Venetoclax (Venclexta) CLL – Patient Group Feedback on Initial Recommendation Feedback March 2, 2018 View PDF
Venetoclax (Venclexta) CLL – Clinician Feedback on Initial Recommendation Feedback March 2, 2018 View PDF
Venetoclax (Venclexta) CLL – Patient Group COI Declarations COI Declarations March 2, 2018 View PDF
Venetoclax (Venclexta) CLL – Clinician COI Declarations COI Declarations March 2, 2018 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : March 19, 2018